Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02922231
Recruitment Status : Recruiting
First Posted : October 4, 2016
Last Update Posted : February 21, 2019
Sponsor:
Information provided by (Responsible Party):
Shire ( Baxalta now part of Shire )

Brief Summary:

Primary: To characterize the safety of RIXUBIS when used under normal clinical care in South Korea.

Secondary: To describe hemostatic effectiveness in subjects receiving RIXUBIS under normal clinical care in South Korea.


Condition or disease Intervention/treatment
Hemophilia B Biological: RIXUBIS

Layout table for study information
Study Type : Observational
Estimated Enrollment : 600 participants
Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Post-Marketing Surveillance (Usage Results Study) of RIXUBIS in Adult and Pediatric Patients With Haemophilia B in South Korea
Actual Study Start Date : January 6, 2017
Estimated Primary Completion Date : April 1, 2019
Estimated Study Completion Date : April 1, 2019

Resource links provided by the National Library of Medicine


Group/Cohort Intervention/treatment
All Study Participants
Participants with congenital hemophilia B (FIX level ≤5%)
Biological: RIXUBIS
Recombinant Factor IX (rFIX) for intravenous use
Other Names:
  • Coagulation Factor IX [Recombinant]
  • rFIX
  • BAX326
  • BAX 326




Primary Outcome Measures :
  1. Number of adverse events (AEs) [ Time Frame: Throughout the study period of approximately 2 years and 6 months ]
    Seriousness and severity of AEs, including any inhibitory antibody development and/or anaphylactic reactions


Secondary Outcome Measures :
  1. Physician rated effectiveness of RIXUBIS for prophylactic treatment in participants <12 years old [ Time Frame: Up to 6 months from baseline while on treatment ]
    Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none

  2. Participant rated effectiveness of RIXUBIS for prophylactic treatment in participants ≥12 years old [ Time Frame: Up to 6 months from baseline while on treatment ]
    Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none

  3. Physician rated effectiveness of RIXUBIS for on-demand treatment in participants <12 years old [ Time Frame: Up to 6 months from baseline while on treatment ]
    Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none

  4. Participant rated effectiveness of RIXUBIS for on-demand treatment in participants ≥12 years old [ Time Frame: Up to 6 months from baseline while on treatment ]
    Rated on a 4-point ordinal scale: Excellent, Good, Moderate, or none



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with hemophilia B in South Korea who have been prescribed RIXUBIS.
Criteria

Inclusion Criteria:

  1. Participants with congenital hemophilia B (FIX level ≤5%)
  2. Participant or the participant's legally authorized representative has provided signed informed consent.
  3. Participant is indicated for treatment according to the RIXUBIS Korean product leaflet.

Exclusion Criteria:

  1. Participants with known hypersensitivity or presence of any contraindication to RIXUBIS or its excipients including hamster protein
  2. Participants with Disseminated Intravascular Coagulation (DIC)
  3. Participants with signs of fibrinolysis

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02922231


Contacts
Layout table for location contacts
Contact: Shire Contact +1 866 842 5335 ClinicalTransparency@shire.com

Locations
Layout table for location information
Korea, Republic of
Daegu Catholic University Medical Center Recruiting
Daegu, Korea, Republic of, 42472
DaeJeon Eulji University Hospital Recruiting
Daejeon, Korea, Republic of, 35233
Chung Hospital Recruiting
Gyeonggi-do, Korea, Republic of, 13316
Contact: Site Contact    +821089588010    mcyookuh@chol.com   
Principal Investigator: Myungchul Yoo         
Kim Hugh Chul Internal Medicine Recruiting
Seoul, Korea, Republic of, 05538
Korea Hemophilia Foundation Recruiting
Seoul, Korea, Republic of, 06641
Sponsors and Collaborators
Baxalta now part of Shire
Investigators
Layout table for investigator information
Study Director: Study Director Shire

Layout table for additonal information
Responsible Party: Baxalta now part of Shire
ClinicalTrials.gov Identifier: NCT02922231     History of Changes
Other Study ID Numbers: 251501
First Posted: October 4, 2016    Key Record Dates
Last Update Posted: February 21, 2019
Last Verified: February 2019

Additional relevant MeSH terms:
Layout table for MeSH terms
Hemophilia A
Hemophilia B
Blood Coagulation Disorders, Inherited
Blood Coagulation Disorders
Hematologic Diseases
Coagulation Protein Disorders
Hemorrhagic Disorders
Genetic Diseases, Inborn
Genetic Diseases, X-Linked